A Monovalent SMAC Mimetic as a Potential Host-Directed Therapy for Tuberculosis
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag031 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Jiahong Ji und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China. Hauptthemen laut MEDLINE: Tuberculosis, Mycobacterium tuberculosis, Mycobacterium bovis, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: State Key Research Development Program of China, Boehringer Ingelheim International GmbH, China Agricultural University.
Abstract (Originalsprache)
Background
Tuberculosis (TB) caused by the Mycobacterium tuberculosis complex (MTBC) is the leading cause of death from a single infectious agent worldwide. Current antibiotics fail against drug-resistant strains, highlighting the urgent need for novel therapies. Host-directed therapy (HDT), which enhances host immunity rather than targeting pathogens directly, offers a promising solution.
Methods
We use the in vitro cells infection assays and in vivo mouse infection model to identify the effects of a monovalent second mitochondria-derived activator of caspase (SMAC) mimetic named BI82 against mycobacterial infections.
Results
We demonstrate that BI82 potently inhibits Mycobacterium bovis growth in macrophages, while exhibiting synergy with rifampicin. BI82 also significantly restricts M. tuberculosis growth in ex vivo whole-blood assays from both tuberculosis patients and healthy donors. BI82 degrades cellular inhibitor of apoptosis protein 1 (cIAP1), promoting infected cell apoptosis as evidenced by elevated cleaved caspase-3 and phosphorylated mixed lineage kinase domain-like levels. In a mouse model, oral BI82 treatment can reduce M. bovis burden in lungs and spleens, alleviate lung lesions, and increase CD3⁺ T cells with elevated CD4/CD8 ratios.
Conclusions
Our findings reveal that BI82 employs a unique apoptosis-dependent mechanism to exert broad-spectrum activity against mycobacterial infections, positioning it as a promising HDT candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.
- National Clinical Laboratory on Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Department of Clinical Laboratory, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Chinese Institutes for Medical Research, Beijing You'an Hospital, Capital Medical University, Beijing, China.
- Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, China.
- Research Beyond Borders, Boehringer Ingelheim, Shanghai, China.
ORCID-Profile: Hairong Huang, Babak Javid, Hao Li
Förderung
- State Key Research Development Program of China
- Boehringer Ingelheim International GmbH
- China Agricultural University
Zitieren
APA
Ji, J., Jiang, X., Liao, X., Du, F., Wang, G., Huang, H., Mei, M., He, Y., Tan, X., Javid, B., & Li, H. (2026). A Monovalent SMAC Mimetic as a Potential Host-Directed Therapy for Tuberculosis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag031
Vancouver
Ji J, Jiang X, Liao X, Du F, Wang G, Huang H, et al. A Monovalent SMAC Mimetic as a Potential Host-Directed Therapy for Tuberculosis. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag031
BibTeX
@article{Ji2026,
author = {Ji, Jiahong and Jiang, Xiaoyi and Liao, Xinlei and Du, Fengjiao and Wang, Guirong and Huang, Hairong and Mei, Miao and He, Yuan and Tan, Xu and Javid, Babak and Li, Hao},
title = {A Monovalent SMAC Mimetic as a Potential Host-Directed Therapy for Tuberculosis},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag031}
}
EUVIMED